A pharmaceutical preparation for the treatment of depression comprises a phenylcyclopropylamine base, preferably in the transconfiguration, or a non-toxic pharmaceutically acceptable acid addition salt thereof, the free base heaving the formula FORM:0911229/VI/1 in which R1 and R2 represent hydrogen or methyl groups, in admixture with a 10-(o -aminoalkyl) phenothiazine free base or a non-toxic pharmaceutically acceptable acid addition salt thereof, the free base having the formula FORM:0911229/VI/2 in which X is hydrogen, chloro, trifluoromethyl, methyl, methoxy or methylthio; A represents propylene or 2-methyl propylene and Z is dimethylamino, methylpiperazinyl, hydroxyethylpiperazinyl, hydroxyethoxyethylpiperazinyl, acetoxyethyl piperazinyl or methylpiperidyl. The salts may be the nitrate, phosphate, citrate, acetate, lactate, mandelate, salicylate, tartrate, ethanedisulphonate, sulphamate, acetylsalicylate, succinate, fumarate, maleate, hydrobromate and benzoate. The preparation is preferably admixed with a solid or liquid pharmaceutical carrier and may take the form of a tablet, capsule, elixir, aqueous injection or dispersion in vegetable oils.
展开▼
